Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Hao Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6489-6940; OpenAlex author ID A5048130149, A5100446031, A5122830851, A5130163158. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
56
Papers, trials and grants by year

2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 6 papers

Papers 12

  1. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
  2. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  3. Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
  4. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
  5. A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. Co-author DOI 10.1158/2326-6066.cir-25-0545↗
  6. Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses. Co-author DOI 10.1158/2326-6066.cir-25-1126↗
  7. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
  8. SREBP-Dependent Regulation of Lipid Homeostasis Is Required for Progression and Growth of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-24-0120↗
  9. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9↗
  10. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer. Last author DOI 10.1158/2767-9764.crc-23-0230↗
  11. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  12. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/2767-9764.crc-22-0343↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elizabeth M. Jaffee · 9 shared papers, 2022–2026 · strength 1.65
  2. Daniel A. Laheru · 9 shared papers, 2022–2026 · strength 1.51
  3. Robert A. Anders · 8 shared papers, 2022–2026 · strength 1.42
  4. Katherine M. Bever · 7 shared papers, 2022–2026 · strength 1.34
  5. Dung Thi Le · 6 shared papers, 2022–2026 · strength 1.09
  6. Won Jin Ho · 5 shared papers, 2026 · strength 1.03
  7. Elana Judith Fertig · 5 shared papers, 2022–2026 · strength 0.93
  8. Jae Woo Lee · 4 shared papers, 2026 · strength 0.83
  9. Amanda L. Huff · 4 shared papers, 2026 · strength 0.81
  10. Mark M. Yarchoan · 4 shared papers, 2025–2026 · strength 0.77
  11. Nilofer Saba Azad · 4 shared papers, 2023–2026 · strength 0.75
  12. Janelle Marie Montagne · 4 shared papers, 2022–2026 · strength 0.71
  13. Ana De Jesus‐Acosta · 4 shared papers, 2022–2025 · strength 0.63
  14. Lei Zheng · 4 shared papers, 2022–2026 · strength 0.62
  15. Amol Kumar Narang · 4 shared papers, 2022–2026 · strength 0.62
  16. Thatcher Ross Heumann · 4 shared papers, 2022–2026 · strength 0.61
  17. Saurav Daniel Haldar · 3 shared papers, 2026 · strength 0.58
  18. Marina Baretti · 3 shared papers, 2026 · strength 0.58
  19. Luciane Tsukamoto Kagohara · 3 shared papers, 2026 · strength 0.58
  20. Neeha Zaidi · 3 shared papers, 2026 · strength 0.58
  21. Richard Andrew Burkhart · 3 shared papers, 2023–2026 · strength 0.52
  22. Arsen Osipov · 3 shared papers, 2022–2026 · strength 0.49
  23. Dimitrios N. Sidiropoulos · 2 shared papers, 2026 · strength 0.42
  24. Jin Peng He · 3 shared papers, 2022–2025 · strength 0.42
  25. Matthew Z. Guo · 2 shared papers, 2025–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.